Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.52 USD | +3.73% | +10.01% | +31.16% |
04-25 | Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients | CI |
04-24 | FTSE 100 keeps the momentum going |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 154.51 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+31.16% | 50.15B | D+ | ||
+8.05% | 3,020B | C+ | ||
+5.58% | 82.93B | B | ||
+3.69% | 76.85B | B+ | ||
-14.62% | 53.04B | B+ | ||
-24.56% | 46.71B | B- | ||
+17.75% | 41.41B | D+ | ||
+55.21% | 36.1B | D+ | ||
-10.24% | 24.64B | C+ | ||
-21.24% | 23.04B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PLTR Stock
- Ratings Palantir Technologies Inc.